KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities (2016 - 2025)

Ionis Pharmaceuticals has reported Other Non-Current Liabilities over the past 12 years, most recently at $28.8 million for Q3 2025.

  • Quarterly results put Other Non-Current Liabilities at $28.8 million for Q3 2025, down 94.65% from a year ago — trailing twelve months through Sep 2025 was $28.8 million (down 94.65% YoY), and the annual figure for FY2024 was $51.9 million, down 89.89%.
  • Other Non-Current Liabilities for Q3 2025 was $28.8 million at Ionis Pharmaceuticals, down from $59.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for IONS hit a ceiling of $538.1 million in Q3 2024 and a floor of $6.9 million in Q4 2021.
  • Median Other Non-Current Liabilities over the past 4 years was $57.4 million (2025), compared with a mean of $240.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 3147.47% in 2024 and later tumbled 94.65% in 2025.
  • Ionis Pharmaceuticals' Other Non-Current Liabilities stood at $6.9 million in 2021, then skyrocketed by 7296.14% to $513.7 million in 2023, then tumbled by 89.89% to $51.9 million in 2024, then crashed by 44.56% to $28.8 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $28.8 million (Q3 2025), $59.1 million (Q2 2025), and $55.7 million (Q1 2025) per Business Quant data.